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TGF-β triggers rapid fibrillogenesis via a 
novel TβRII-dependent fibronectin-trafficking 
mechanism
ABSTRACT Fibronectin (FN) is a critical regulator of extracellular matrix (ECM) remodeling 
through its availability and stepwise polymerization for fibrillogenesis. Availability of FN is 
regulated by its synthesis and turnover, and fibrillogenesis is a multistep, integrin-dependent 
process essential for cell migration, proliferation, and tissue function. Transforming growth 
factor β (TGF-β) is an established regulator of ECM remodeling via transcriptional control of 
ECM proteins. Here we show that TGF-β, through increased FN trafficking in a transcription- 
and SMAD-independent manner, is a direct and rapid inducer of the fibrillogenesis required 
for TGF-β–induced cell migration. Whereas TGF-β signaling is dispensable for rapid fibrillo-
genesis, stable interactions between the cytoplasmic domain of the type II TGF-β receptor 
(TβRII) and the FN receptor (α5β1 integrin) are required. We find that, in response to TGF-β, 
cell surface–internalized FN is not degraded by the lysosome but instead undergoes recycling 
and incorporation into fibrils, a process dependent on TβRII. These findings are the first to 
show direct use of trafficked and recycled FN for fibrillogenesis, with a striking role for TGF-β 
in this process. Given the significant physiological consequences associated with FN avail-
ability and polymerization, our findings provide new insights into the regulation of fibrillo-
genesis for cellular homeostasis.
INTRODUCTION
The extracellular matrix (ECM) is a key player in regulating cell dif-
ferentiation, growth, and motility during wound-healing and fi-
brotic responses. Growth factors, particularly transforming growth 
factor β (TGF-β), can regulate the ECM by increasing fibronectin 
(FN) synthesis (Ignotz and Massague, 1986; Allen-Hoffmann et al., 
1988; Roberts et al., 1988; Bortell et al., 1994; Hocevar and Howe, 
2000; Biname et al., 2008). The bulk of TGF-β transcriptional re-
sponses, including FN transcription, are mediated through phos-
phorylation-dependent activation of the type I receptor (TβRI/
ALK5) and SMAD2/3 or SMAD1/5 (Ignotz and Massague, 1986; de 
Caestecker, 2004; Daly et al., 2008), which requires the constitu-
tive kinase activity of the type II receptor (TβRII; Massague et al., 
1991).
FN produced by the cell can be assembled in a stepwise manner 
by most cell types to produce matrix-associated FN in a process 
termed fibrillogenesis (Mao and Schwarzbauer, 2005). In addition to 
providing a structural scaffold, fibrillogenesis is key to physiological 
cell repair, motility, and adhesion, thus making it a highly regulated 
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RESULTS
TGF-β1 and TGF-β2 rapidly increase fibrillogenesis
To investigate the effects of TGF-β on FN fibrillogenesis, we used 
two approaches: biochemical fractionation of soluble (S) FN and the 
fibril-associated insoluble pellet (P) FN using the detergent deoxy-
cholate (DOC fractionation; Sechler et al., 1996) and immunofluo-
rescence microscopy to visualize FN localization and fibrillogenesis. 
Using these methods in human foreskin fibroblast cells (HFFs), an 
established cell line for FN matrix assembly (Clark et al., 2005), we 
find that, in response to a 30-min TGF-β treatment, soluble (S) FN 
levels decreased, with a compensatory increase in (P) FN levels 
(Figure 1A). Immunolabeling of FN also revealed an increase in the 
appearance of FN fibrils in response to both TGF-β1 and TGF-β2 
(Figure 1B), in accordance with the biochemical fractionation (Figure 
1A). Consistent with the effect of TGF-β in HFF cells, a similar in-
crease in FN- and DOC-insoluble (P) fraction of FN was observed in 
response to both TGF-β1 and TGF-β2 in nonfibroblast MCF10A epi-
thelial cells (Figure 1, C and D, top, –cycloheximide [CHX]). These 
findings suggest a rapid response to TGF-β for fibrillogenesis in di-
vergent cell types.
Prior studies in fibroblasts indicated that FN assembly by TGF-β 
can occur in the absence of protein synthesis (Allen-Hoffmann et al., 
1988). To examine whether TGF-β stimulated FN assembly within 
30 min and was independent of protein synthesis in epithelial 
MCF10A cells as well, we investigated FN localization in the pres-
ence of CHX, the protein synthesis inhibitor (Figure 1D, bottom, and 
Supplemental Figure S1A). CHX treatment did not inhibit TGF-β–
mediated increases in the appearance of FN fibrils (Figure 1D, 
+CHX). Consistent with no requirement for new FN synthesis, total 
pools of FN did not increase in cells after treatment with TGF-β for 
30 min (Figure 1E). TGF-β1– and TGF-β2–induced increase in the 
DOC-insoluble (P) fraction of FN in MCF10A epithelial cells also re-
mained high even in the presence of CHX (Supplemental Figure 
S1A). These findings indicate that TGF-β–induced fibrillogenesis in 
epithelial cells can be protein synthesis independent. We observed 
no specific accumulation of cells in any phase of the cell cycle that 
could have contributed to fibrillogenesis in response to 30 min of 
TGF-β stimulation (Supplemental Figure S1B). To confirm that the 
TGF-β–induced fibrils were indeed at the cell surface in MCF10A 
cells, we used total internal reflection fluorescence (TIRF) micros-
copy to image and quantify cell surface FN. In agreement with 
Figure 1C, we observed a significant increase in cell surface FN in 
response to TGF-β1 and TGF-β2 (Figure 1F). Quantitation of distinct 
FN structures on the cell surface was performed using a length of 3 
µm as a threshold for cut-off (Coussen et al., 2002; Lutz et al., 2011; 
Materials and Methods). This criterion was used in all subsequent 
analyses of MCF10A cells. Cells with FN fluorescent puncta less than 
the threshold length were classified as cells lacking FN fibrils. This 
method of quantification was in accordance with our DOC fraction-
ation observations (Figure 1, A and C), as TGF-β1 and TGF-β2 sig-
nificantly increased the number of quantifiable FN fibrils compared 
with control cells (Figure 1G). To establish firmly that TGF-β was en-
hancing fibrillogenesis in MCF10A cells, we treated TGF-β–stimu-
lated cells with either the functional upstream domain (FUD) pep-
tide (a short 49-mer that binds the N-terminal sites on FN to block 
fibril assembly) or a matched control peptide IIIC (Tomasini-Johans-
son et al., 2006; Shi et al., 2014) as described in Materials and 
Methods. DOC fractionation of the soluble (S) FN and the fibril-as-
sociated insoluble pellet (P) FN (Figure 1H) and immunofluores-
cence (Figure 1I) revealed that the FUD peptide significantly abol-
ished the observed fibril assembly mediated by TGF-β in epithelial 
cells compared with either TGF-β alone or TGF-β in the presence of 
process affected by the availability of FN, activation state of the FN 
receptor, and rate of remodeling (Schwarzbauer and Sechler, 1999; 
Schwarzbauer and DeSimone, 2011). Availability and balance of 
soluble and matrix-incorporated FN are also critical because soluble 
or dimeric FN can drive the epithelial-to-mesenchymal transition, 
whereas matrix-associated polymeric FN can decrease cancer cell 
invasiveness (Ruoslahti, 1984; Saulnier et al., 1996; Shi et al., 2014). 
Such opposing functions point to the significance of soluble versus 
matrix FN regulation.
Several studies have examined the molecular requirements and 
dynamic nature of fibrillogenesis and its biomechanical properties 
(Erickson et al., 1981; Erickson and Carrell, 1983; Lotz et al., 1989; 
Danen et al., 2002; Mao and Schwarzbauer, 2005). Initiation and 
completion of fibrillogenesis are not always very efficient processes 
because a significant portion of FN that is engaged with its receptor 
might not be used/incorporated into fibrils (Pankov et al., 2000). 
However, once incorporated, remodeling of matrix-incorporated FN 
can also occur at the level of protein turnover via either endocytosis-
dependent lysosomal degradation of FN (Sottile and Chandler, 
2005) or during changes in spatiotemporal control of fibrillogenesis. 
Such remodeling events determine cellular responses, as seen in 
epithelial branching morphogenesis, in which both synthesis and 
transient assembly of FN are observed at cleft-forming sites (Sakai 
et al., 2003).
Integrins play key roles in fibrillogenesis: α5β1, α8β1, αvβ1, 
αvβ3, αIIbβ3, αvβ5, αvβ6, and αvβ8 all recognize the common in-
tegrin-binding motif Arg-Gly-Asp (RGD), which is found in many 
ECM components, including FN (Danen and Sonnenberg, 2003). 
α5β1, however, is most efficient in mediating FN matrix assembly, 
with compensation from other integrins also possible in the ab-
sence of α5β1 (Wu et al., 1996; Yang and Hynes, 1996). We and 
others have also reported several interactions between the TGF-β 
and integrin pathways that occur through SMAD-independent 
mechanisms and can affect integrin signaling (Hocevar et al., 1999; 
Bhowmick et al., 2001; Galliher and Schiemann, 2006, 2007; 
Galliher-Beckley and Schiemann, 2008; Garamszegi et al., 2010; 
Huck et al., 2010; Mythreye et al., 2013).
Whereas prior studies examined mechanisms of FN turnover 
and suggested specific trafficking regulation of ECM compo-
nents as a mechanism for increased matrix assembly (Abraham 
et al., 2004; Sottile and Chandler, 2005; Unlu et al., 2014), 
whether non–matrix-incorporated, soluble ECM components 
are capable of returning to the cell surface has yet to be deter-
mined. Here we show that a rapid fibrillogenesis response to 
TGF-β in both nonmotile and motile cells precedes transcrip-
tionally induced fibrillogenesis. We find that one mechanism for 
this nontranscriptional fibrillogenesis is via increased FN uptake 
and recycling of soluble FN. Our results reveal that internalized 
FN can recycle through a Rab11-dependent mechanism for fi-
brillogenesis, particularly in response to TGF-β stimulation. Of 
note, recycled and trafficked FN can constitute a significant por-
tion of matrix-incorporated FN. We also find that TGF-β–in-
duced rapid fibrillogenesis is largely independent of SMAD acti-
vation but requires TβRII to mediate FN recycling. Specifically, 
we show that this process occurs through a TβRII-α5β1–depen-
dent interaction that is disrupted in the TβRII mutant lacking the 
cytoplasmic domain required for trafficking. From a broad per-
spective, our findings suggest that discrete sources of soluble 
FN could be used to build and assemble a FN matrix, which may 
directly affect growth factor–regulated matrix assembly and, ul-
timately, the rate and extent of cell differentiation, growth, and 
motility.
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a control peptide (Figure 1I and Supple-
mental Figure S1C)
Given that the immunofluorescence of 
FN and DOC fractionation were examined 
in nonmigrating cells and the established 
role of TGF-β in epithelial cell migration 
(Wang et al., 2005; Park and Schwarzbauer, 
2014), we next investigated the effect of fi-
brillogenesis in migrating epithelial cells. To 
test this, we carried out a Transwell migra-
tion assay for 6 h in the presence of exoge-
nously added rhodamine-FN (Rh-FN; 
Materials and Methods). We found that cells 
that migrated in the presence of TGF-β 
showed distinct Rh-FN fibrils, in contrast to 
cells that migrated without TGF-β (Figure 
1J). TGF-β–induced fibril formation in mi-
grating cells was disrupted in the presence 
of FUD (Shi et al., 2014), indicating that 
TGF-β increased FN assembly in migrating 
cells as well. Moreover, TGF-β–induced cell 
migration was disrupted by the FUD pep-
tide (Figure 1K). The control IIIC peptide did 
not affect cell migration (Figure 1K) or fibril-
logenesis (Supplemental Figure S1C), con-
sistent with prior reports (Chiang et al., 
2009; Singh and Schwarzbauer, 2014). To-
gether, these data suggest that TGF-β trig-
gers rapid fibrillogenesis in migrating cells 
that is independent of new protein 
synthesis.
TGF-β type II receptor is required 
for fibrillogenesis
Because TGF-β1 and TGF-β2 treatments 
increase fibrillogenesis, we sought to de-
termine whether this was mediated via the 
TGF-β receptor serine threonine kinases, 
which regulate both SMAD-dependent and 
SMAD-independent signaling (Massague, 
2012). To test the contribution of the kinase 
activity of the type I TGF-β receptor, we 
used MCF10A cells and biochemically 
quantified the (S) and (P) FN fractions of 
FIGURE 1: TGF-β1 and TGF-β2 rapidly increase fibrillogenesis. (A, B) HFFs were treated with 
TGF-β1 or TGF-β2 for 30 min and (A) DOC extraction used to fractionate DOC-soluble (S) and 
-insoluble (pellet (P)) pool and immunoblotted for FN, or (B) cells were immunostained using 
anti-FN. Right, average fibril number (Materials and Methods) in untreated (UN), TGF-β1–, or 
TGF-β2–treated cells. Fibril lengths were tracked using the NeuronJ plug-in on ImageJ. 
(Materials and Methods). (C) MCF10A cells treated with TGF-β1 or TGF-β2 for 30 min and 
processed for DOC extraction and immunoblotted for (S) and (P) FN as in A. (D) MCF10A cells 
untreated or treated with 10 ng/ml TGF-β1 or TGF-β2 for 30 min (with or without preincubation 
with 20 µg/ml CHX for 2 h) and immunostained for endogenous FN. Right, average fibril number 
in untreated (UN), TGF-β1–, or TGF-β2–treated cells. Fibril lengths were tracked using the 
NeuronJ plug-in on ImageJ. Scale bar, 5 µm. (E) Total MCF10A cell lysates at the indicated 
treatment times were lysed in SDS buffer to solubilize total FN pools ((S) and (P) combined) and 
immunoblotted against FN. Vinculin was used as the loading control. (F) Cells treated as in A 
and imaged using TIRF microscopy (penetration depth, 110 nm). Scale bar, 5 µm. (G) Average 
fibril number analyzed from TIRF images in untreated (UN), TGF-β1–, or TGF-β2–treated cells. 
Fibril lengths from F were tracked using the NeuronJ plug-in on ImageJ. (H, I) MCF10A cells 
were treated with 10 ng/ml TGF-β1 for 30 min (with or without 500 nM FUD peptide or the 
matched control IIIC peptide) and processed either (H) for DOC extraction and immunoblotting 
for (S) and (P) FN (actin was the loading control from the soluble pool) or (I) immunostained for 
FN. (J) MCF10A cells allowed to migrate for 6 h in the presence of Rh-FN as indicated in the 
figure. Migrated cells are captured by fixing 
the cells on the Transwell filter. Images of 
Rh-FN are representative of at least four 
different fields on the filter from two 
independent biological trials. Scale bar, 5 µm. 
(K) Transwell migration through FN-coated 
Transwells of MCF10A for 12 h either 
untreated or in the presence of TGF-β1 alone 
or with either control IIIC peptide or FUD 
peptide as in J and as indicated. Migrated 
cells were counted and plotted relative to 
untreated filters. Asterisks indicate significant 
differences as indicated (*p < 0.05, 
**p < 0.01, ***p < 0.001). Quantitation of 
blots is representative of a minimum of three 
independent trials.
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either all three receptors (TβRI, TβRII, and 
TβRIII; Mv1Lu), only TβRII and TβRIII (R1b), 
or only TβRI and TβRIII (DR; Boyd and 
Massague, 1989; Laiho et al., 1990; Wrana 
et al., 1992), and qualitatively examined 
steady-state fibrillogenesis. Immunolabel-
ing of FN (Figure 2B) revealed that Mv1Lu 
and R1b cells showed distinct and punctate 
patterns of short FN fibrils, much like un-
treated MCF10A cells (Figure 1D). DR cells, 
which lack TβRII, showed little to no FN fi-
brils, with only diffuse FN observed (Figure 
2B) compared with Mv1Lu cells. Biochemi-
cal fractionation of the fibrils showed the 
least DOC-insoluble pellet fraction in the 
DR cells, with significantly higher amounts 
of pellet in the R1b cells that do not ex-
press TβRI/ALK5, despite relatively equal 
amounts of total FN (Figure 2C, bottom). 
All three cell lines expressed the primary 
fibronectin receptors integrin α5β1 (Sup-
plemental Figure S2B) and were also re-
ported to express other FN receptors 
(Garamszegi et al., 2010). These data sug-
gest that the differences observed could in 
part be due to differences in TβRII levels. 
To confirm this hypothesis and a role for 
TβRII, we transiently suppressed TβRII ex-
pression in MCF10A cells using different 
short hairpin RNAs (shRNAs) to TβRII 
(shTβRII-1, shTβRII-2, or in combination for 
greater knockdown; Figure 2D) and DOC-
fractionated MCF10A cells to evaluate rela-
tive (S) and (P) FN fractions (Figure 2E) or 
examine FN by immunolabeling (Figure 
2F). TGF-β1 was unable to increase the FN 
in the (P) pool in shTβRII cells compared 
with shScr cells (Figure 2E) or increase the 
appearance of FN fibrils (Figure 2F). Quan-
titation of fibrils in MCF10A shTβRII-1 and 
2 cells treated with TGF-β revealed a four-
fold decrease in the percentage of cells 
containing fibrils compared with control 
cells (N = 200; Figure 2, F and G), in concur-
rence with the DOC fractionation, indicat-
ing a requirement for TβRII in TGF-β–in-
duced fibrillogenesis. shScr cells also 
exhibited a statistically higher number of 
cells containing fibrils in untreated condi-
tions compared with shTβRII cells (***p < 
0.001; Figure 2G). These results and the reduced baseline fibril 
fraction in DR cells (Figure 2, B and C) suggest that fibrillogenesis 
requires TβRII.
TβRII’s cytoplasmic domain is required for interactions with 
integrin α5 and fibrillogenesis
Given the central role of integrin α5β1 in fibrillogenesis (Wennerberg 
et al., 1996; Yang et al., 1999) and the new role for TβRII in fibrillo-
genesis (Figure 2), we tested whether TβRII and integrin α5β1 re-
ceptors act in concert to mediate fibrillogenesis. To determine 
whether TβRII interacted with the subunits of the FN receptor (α5β1) 
at the cell surface, we carried out patch/fluorescence recovery after 
untreated and TGF-β–treated cells in the presence of SB431542, a 
type I TGF-β receptor kinase (TβRI/ALK5) inhibitor that blocks 
SMAD2/3 and SMAD1/5 activation (Supplemental Figure S2A; 
Daly et al., 2008). We observed an increase in the insoluble (P) frac-
tion in the presence of SB431542 (Figure 2A), indicating that rapid 
fibrillogenesis is independent of TβRI kinase activity. We previously 
reported that regulation of fibrillogenesis by the TGF-β type III re-
ceptor (TβRIII) depends on the type II TGF-β receptor (TβRII; 
Mythreye et al., 2013). In addition, TβRII is a well-established tar-
get of integrin signaling (Galliher and Schiemann, 2007). Hence, to 
test the cellular relevance of TβRI and TβRII to fibrillogenesis, we 
used the mink lung series of epithelial cell lines, which express 
FIGURE 2: TβRII is required for fibrillogenesis. (A) MCF10A cells were preincubated with 3 µM 
SB431542 for 30 min before treatment with 10 ng/ml TGF-β1 for 30 min. Lysates were DOC 
fractionated and immunoblotted for FN. Actin was the loading control for the (S) fraction. 
(B, C) Either (B) Mink lung epithelial cells MV1Lu (wild type [WT] for type I, II, III TGF-β 
receptors), R1b (WT for type II, III), and DR (WT for type III)) were immunostained for FN or 
(C) cell lysates were DOC fractionated and immunoblotted for FN in the soluble (S) and 
insoluble (P) pools. Arrowheads indicate short fibrils and focal contacts. Scale bar, 5 µm. 
Immunoblot below in C shows total FN levels ((S) and (P) fractions combined) in the Mink lung 
cell lines. Vinculin was the loading control. (D) TβRII levels in MCF10A cells transfected with 
shRNAs to TβRII (shTβRII-1 and 2) or shScr to examine efficacy of knockdown. (E) Indicated 
MCF10A cells were treated with TGF-β1 (10 ng/ml for 30 min), DOC extracted into the (S) and 
(P) fractions, and immunoblotted for FN. Numbers for soluble (S) fraction are normalized to actin 
and pellet (P) relative to the normalized soluble pool in untreated conditions. Quantitation of 
blots is representative of three independent trials. (F) Cells transfected with shRNAs to TβRII 
(shTβRII-1 and 2) or shScr were left untreated or treated with TGF-β1 (10 ng/ml for 30 min) and 
immunostained for FN. Representative images. Scale bar, 3.7 µm. (G) Percentage of fibril-
containing cells in the indicated conditions were quantified and plotted. Asterisks indicate 
significant differences (t test) between untreated and TGF-β1–treated samples in shScr 
transfectants (*p < 0.001) and between untreated and TGF-β1–treated samples in shTβRII 
(shTβRII-1 and 2) transfectants (*p < 0.001). Data are representative of two independent 
experiments.
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photobleaching (FRAP) analyses (Henis et al., 1990; Rechtman 
et al., 2009) between integrin α5 or β1 and TβRII. This method in-
volves patching and immobilizing one receptor by cross-linking with 
a double layer of immunoglobulin Gs (IgGs) and then determining 
the effect on the lateral diffusion of a coexpressed membrane pro-
tein, which is labeled, immobilized (in this case, by red fluorescent 
protein [RFP] or green fluorescent protein [GFP]), and measured by 
FRAP (Materials and Methods). Formation of mutual complexes be-
tween these proteins can reduce either the mobile fraction (Rf) or 
lateral diffusion coefficient (D) of the un-cross-linked protein, de-
pending on the FRAP time scale relative to the rate of dissociation/
association of the oligomer. Complex lifetimes longer than the char-
acteristic FRAP times (stable interactions) result in reduced Rf with-
out affecting D because bleached molecules of the un-cross-linked 
protein do not markedly dissociate from the immobile clusters dur-
ing the FRAP measurements. On the other hand, short complex life-
times (transient interactions) lead to several association/dissociation 
cycles for each fluorescence-labeled molecule during the FRAP 
measurement, resulting in lower D without affecting Rf. We coex-
pressed myc-TβRII and integrin α5-RFP (or β1-GFP) in COS7 cells 
and subjected the cells to patch/FRAP measurements with or with-
out IgG cross-linking of myc-TβRII in the presence or absence of FN 
(Figure 3A). Integrin α5-RFP expressed alone or with myc-TβRII in 
the absence of IgG cross-linking exhibited similar and high lateral 
diffusion in the plasma membrane, with a high mobile fraction 
(0.91). IgG-mediated patching of myc-TβRII rendered the latter lat-
erally immobile (Figure 3Aiv) and led to a significant reduction in Rf 
of integrin α5-RFP (to 0.82; Figure 3Av) without affecting the D val-
ues, which were all within the range of 0.1 ± 0.02 µm2/s (unpub-
lished data). Such an effect is characteristic of stable interactions 
(Henis et al., 1990; Rechtman et al., 2009) between integrin α5 and 
TβRII in a fraction of the total cell surface pool. Incubation with FN 
somewhat further reduced the Rf values (a reduction of 0.09–0.13). 
However, the additional reduction was mainly due to a marginally 
higher Rf value before IgG cross-linking, indicating that steady-state 
interactions between TβRII and α5 are not largely increased by the 
presence of exogenous FN. Of note, an analogous reduction was 
observed in Rf of integrin β1-GFP upon cross-linking of coexpressed 
myc-TβRII (Figure 3Avi). The only difference was that, in this case, 
addition of FN sufficed to immobilize part of the β1-GFP cell surface 
population, possibly due to the multimeric nature of FN, which can 
cluster integrin β1 and target it to cytoskeletal structures (McKeown-
Longo and Mosher, 1984; Bhatia et al., 1999; Eisenberg et al., 2011). 
These findings suggest that TβRII interacts stably at the cell surface 
with integrin α5β1 and this interaction persists in the presence of 
FN. Moreover, the interaction is exclusively with TβRII because simi-
lar studies cross-linking the type I TGF-β receptor (myc-TβRI) with 
integrin α5-RFP did not affect integrin α5 mobility (Figure 3Avii).
Because the cytoplasmic domain of TβRII is critical for TβRII traf-
ficking (Murphy et al., 2007) and is also a substrate for non–TGF-β 
receptor kinases (Galliher and Schiemann, 2007), we tested the role 
of the cytoplasmic domain of TβRII in facilitating the interaction 
between TβRII and α5. Patch/FRAP analysis of the interactions be-
tween myc-TβRII S199, which contains 10 amino acids of the cyto-
plasmic tail undergoing normal processing and transport to the cell 
surface (Ehrlich et al., 2001), and integrin α5-RFP (Figure 3Aviii) re-
vealed that the lateral diffusion of integrin α5-RFP was unaffected 
by immobilization of coexpressed TβRII S199, suggesting loss of 
TβRII S199 and α5 interaction (Figure 3Aviii). To test whether the 
TβRII–integrin α5 interaction mediated by the cytoplasmic domain 
influenced fibrillogenesis in MCF10A cells, we first confirmed the 
interaction between endogenous TβRII and endogenous α5 using 
coimmunoprecipitation (Figure 3B). We then examined fibrillogen-
esis in cells expressing TβRII S199, the complete truncation of the 
TβRII cytoplasmic domain (TβRII ∆Cyto) (Siegel et al., 2003), or con-
trol pcDNA. We found that both TβRII ∆Cyto– and TβRII S199–ex-
pressing MCF10A cells were depleted of fibrils at steady state and 
failed to mount an increase in FN fibrils in response to TGF-β1 
treatment compared with control (pcDNA) cells (Figure 3C). To in-
vestigate whether the kinase activity of TβRII, which is necessary for 
optimal internalization (Anders et al., 1998), is required for TGF-β–
induced fibrillogenesis, we used the TβRII point mutant K277R 
(TβRIIK277R-HA) and tested interaction with integrin α5 using co-
immunoprecipitation. We found that, whereas exogenously ex-
pressed TβRII-HA in COS7 cells coimmunoprecipitated integrin α5 
(Figure 3D), as observed with endogenous receptors in MCF10A 
cells (Figure 3B), TβRIIK277R was less efficient at immunoprecipitat-
ing integrin α5, suggesting a requirement for TβRII kinase activity in 
the TβRII–integrin α5 interaction. Moreover, similar to the effect of 
TβRII S199 and TβRII ∆Cyto, expressing TβRIIK277R in MCF10A 
cells resulted in reduced fibrillogenesis in response to TGF-β 
(Figure 3E). Taken together, these data suggest that the specific, 
stable interaction between integrin α5 and TβRII requires the cyto-
plasmic domain and kinase activity of TβRII for TGF-β–mediated 
fibrillogenesis.
TGF-β increases FN internalization and recycling 
for fibrillogenesis
The cytoplasmic domain of TβRII, which is critical for TβRII traffick-
ing (Ehrlich et al., 2001; Rechtman et al., 2009), is also required for 
stable interactions with integrin α5 (Figure 3), which can be bound 
to FN in early endosome antigen 1 (EEA1)–positive endosomes 
and multivesicular endosomes (Lobert et al., 2010). Several studies 
indicated that various forms of exogenously added FN are internal-
ized and localized to distinct cellular compartments in fibroblasts 
(Sottile and Chandler, 2005; Lobert et al., 2010; Bozavikov et al., 
2014). However, whether FN trafficking is directly required for fibril-
logenesis is not known. Given the FN synthesis–independent re-
sponse to TGF-β–induced fibrillogenesis (Figure 1) and the effect 
of the cytoplasmic domain of TβRII, which is critical for TβRII traf-
ficking (Ehrlich et al., 2001; Penheiter et al., 2002; Mitchell et al., 
2004) and now in FN receptor interactions and fibrillogenesis 
(Figure 3), we tested whether FN trafficking was required for fibril-
logenesis in response to TGF-β. To first investigate whether FN is 
internalized to different extents in the presence of TGF-β, we al-
lowed the uptake of Rh-conjugated fibronectin (Rh-FN; Materials 
and Methods) for 30 min, followed by acid stripping to remove cell 
surface FN, which we confirmed using TIRF microscopy (Supple-
mental Figure S2C), to retain only the internalized pool of FN. We 
observed a twofold increase (*p < 0.05) in the internalized pool of 
Rh-FN between untreated and TGF-β1–treated cells and a three-
fold increase (**p < 0.01) between untreated and TGF-β2–treated 
cells within 30 min (Figure 4, A and B). Because exogenous FN 
added to FN-null cells was previously shown to be degraded by the 
lysosome (Sottile and Chandler, 2005), we tested whether internal-
ized FN in epithelial cells is also degraded in response to a 30-min 
TGF-β treatment. Lysosomal protein LAMP1 immunolabeling re-
vealed significant FN exclusion (Figure 4C), suggesting that the 
bulk of internalized FN is not localized to the lysosome upon 
TGF-β1 and TGF-β2 treatments. In addition, a 6-h lysosomal inhibi-
tion with chloroquine (CQ) in TGF-β–treated cells did not signifi-
cantly increase total FN levels beyond TGF-β–induced FN tran-
scriptional induction (Figure 4D, compare lanes 3 and 4; and 5 and 
6), indicating that lysosomal degradation of FN does not occur 
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within 6 h of TGF-β1 or TGF-β2 treatment, 
the time period well within nontranscrip-
tional fibrillogenesis (Figure 1).
Given the TGF-β–induced increase in FN 
uptake, LAMP1 exclusion of internalized FN, 
and rapid increase in fibrillogenesis (Figures 
1, A and B, and 4, A and C), we asked 
whether internalized FN could contribute di-
rectly to matrix-incorporated (DOC-insolu-
ble) (P) FN. To test this, we used biotinylated 
FN (FN-biotin) and streptavidin-conjugated 
secondary antibody to biochemically quan-
tify only the exogenously added FN-biotin 
(Materials and Methods). Because Rh-FN 
can be internalized within 30 min (Figure 
4A), we allowed uptake of FN-biotin for 30 
min, followed by repeated washes to re-
move unbound FN-biotin from the cell sur-
face. The cells were then allowed to recover 
for 1 h in FN-biotin–free medium in the pres-
ence of either serum alone (UN), TGF-β1, 
or TGF-β2 to test the effect of TGF-β on 
FIGURE 3: TβRII’s cytoplasmic domain is required for steady-state interactions with integrin 
α5β1 and fibrillogenesis. (A) COS7 cells were cotransfected with expression vectors encoding 
myc-TβRII, myc-TβRII S199, or myc-TβRI and integrin α5-RFP or β1-GFP. In control experiments, 
the integrin construct was replaced by empty vector. At 48 h after transfection, live cells were 
incubated without or with FN and subjected (or not) to IgG-mediated patching/cross-linking of 
myc-TβRII or myc-TβRI (Materials and Methods), resulting in Alexa 488 (or 546)–labeled myc–
TGF-β receptor patched and laterally immobile (iv). In control experiments without cross-linking, 
the IgG labeling of the myc-TGF-β receptor was replaced by exclusive Fab’ labeling (replacing 
the cross-linking IgGs by their respective Fab’ fragments). FRAP studies were conducted on 
integrin α5–RFP or β1–GFP at 15°C to minimize internalization. The confocal nature of the FRAP 
experimental setup enabled the measurement of integrin fluorescence recovery exclusively at 
the plasma membrane (avoiding internal vesicles or ER fluorescence). The laser beam was 
focused on the upper cell surface and away from cell edges, thus avoiding focal adhesions. Solid 
lines are the best fit of a nonlinear regression analysis to the lateral diffusion equation (Rechtman 
et al., 2009). (i) Representative FRAP curve of the lateral diffusion of integrin α5-RFP in a cell 
coexpressing myc-TβRII (no IgG cross-linking). (ii) A FRAP curve of integrin α5-RFP in a cell 
coexpressing myc-TβRII immobilized by IgG 
cross-linking. (iii) A FRAP curve of the lateral 
diffusion of myc-TβRII. (iv) A FRAP curve of 
the lateral diffusion of myc-TβRII immobilized 
by IgG cross-linking. (v–viii) Average Rf values 
derived from multiple patch/FRAP 
measurements (coexpressed receptor pairs 
are indicated above each graph). Because 
the D values were unaffected in all cases 
(0.1 ± 0.02 µm2/s), they are not shown. Bars 
are mean ± SEM of 30–50 measurements in 
each case. Asterisks indicate significant 
differences between the Rf values of the pair 
indicated by brackets (*p < 0.001; Student’s 
t test). (B) MCF10A cells were immuno-
precipitated with integrin α5 antibody or IgG 
as control and immunoblotted as indicated 
for endogenous TβRII and integrin α5. Input 
loading control was actin. (C) MCF10A cells 
transfected with empty vector or TβRII ∆Cyto 
or TβRII S199 were treated with TGFβ1 
(10 ng/ml for 30 min) and coimmunostained 
using anti-HA (green) to identify transfected 
cells and anti-FN to endogenous FN (red). 
Scale bar, 5 µm. Quantitation of percentage 
of fibril-containing cells (Materials and 
Methods) in the indicated conditions; N > 
200. (D) COS7 cells transfected for 48 h with 
indicated TβRII constructs followed by 
immunoprecipitation with anti-α5 antibody 
and immunoblotted using either anti-HA or 
anti-α5 as indicated. (E) MCF10A cells 
transfected with empty vector or TβRII 
K277R were treated with TGFβ1 (10 ng/ml 
for 30 min) and coimmunostained using 
anti-HA (green) to identify transfected cells 
and anti-FN to endogenous FN (red). Scale 
bar, 4 µm. Quantitation of percentage of 
fibril-containing cells (Materials and Methods) 
in the indicated conditions; N > 50.
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incorporation of internalized FN-biotin into 
a DOC-insoluble (P) fraction. DOC fraction-
ation of the soluble (S) and insoluble (P) frac-
tions revealed that, compared with un-
treated cells, there was a twofold increase in 
the (P) insoluble fraction after TGF-β1 and 
TGF-β2 stimulation (compare lanes 2, 4, and 
6 in Figure 4E). Because TGF-β treatments 
were carried out in the absence of additional 
FN-biotin and exogenous FN can be inter-
nalized in the presence of TGF-β (Figure 4, A 
and B), these data suggest that TGF-β can 
increase fibrillogenesis by using an internal-
ized pool of FN-biotin that is recycled to 
form fibrils.
To confirm that the insoluble fraction (P) 
detected by DOC in the foregoing experi-
ment came from the internalized pool, we 
carried out a recycling assay (Figure 4F, 
schematic) using labeled Rh-FN, which can 
be visualized (Weigert and Donaldson, 
2005). Internalization and cell surface re-
moval of Rh-FN was carried out by acid 
stripping (Materials and Methods). Images 
in the Epi mode versus the TIRF mode con-
firmed internalized Rh-FN (Figure 4G) be-
cause no Rh-FN was observed on TIRF 
mode (Figure 4G). These results indicate 
that cells internalized Rh-FN within 30 min, 
and acid washing of the cells completely 
depleted surface Rh-FN. To test our predic-
tion from Figure 4E that TGF-β enhanced 
FN recycling, we incubated acid-stripped 
cells, which now contained only internal-
ized Rh-FN (Figure 4G, left, MCF10A cells), 
with media containing serum (UN), TGF-β1, 
or TGF-β2 (Figure 4G and Supplemental 
Figure S2D). Compared to untreated cells, 
TGF-β1 substantially increased the appear-
ance of Rh-FN at the cell surface after 1 h of 
treatment in MCF10A cells (Figure 4G). 
This observation was not restricted to epi-
thelial cells because TGF-β1 also induced 
recycling of FN to the cell surface in HFF 
cells (Figure 4G, right). Similarly, TGF-β2 
also increased Rh-FN recycling (Supple-
mental Figure S2D). These findings lead us 
to conclude that TGF-β stimulates internal-
ization and recycling of FN (Figure 4, A and 
G) for fibrillogenesis.
FIGURE 4: TGF-β increases FN internalization and recycling for fibrillogenesis. (A) Rh-FN at 
20 µg/ml was added to MCF10A cells either untreated or in the presence of TGF-β1 and TGF-β2 
for 30 min, followed by stripping of cell surface Rh-FN (Materials and Methods). Representative 
fluorescence images of Rh-FN. Scale bar, 5 µm. Arrows indicate internalized Rh-FN. 
(B) Quantification of integrated fluorescence intensity of Rh-FN normalized to cell area from cells 
in A; N > 100/condition. Significance was calculated between untreated samples and TGF-β1– 
(*p < 0.05) and TGF-β2–treated (**p < 0.01) samples using the Mann–Whitney U test. Data are 
representative of at least three independent experiments. (C) MCF10A cells treated with 
TGF-β1/TGF-β2 (10 ng/ml, 30 min) were coimmunostained using anti-LAMP1 and anti-FN; 
images acquired using confocal microscopy. Scale bar, 5 µm. (D) MCF10A cells were treated with 
TGF-β1 or TGF-β2 for 6 h with or without 100 µM CQ. Lysates were immunoblotted for total FN. 
Vinculin was used as loading control. (E) Representative DOC-fractionated biotinylated FN 
(FN-biotin; Materials and Methods) in MCF10A cells. FN-biotin at 20 µg/ml was added to cells 
for 30 min and washed to remove nonspecific FN-biotin binding on the cell surface. The cells 
were then reincubated in FN-biotin–free medium for 1 h with or without TGF-β1 or TGF-β2, 
DOC fractionated into (S) and (P) fractions, and immunoblotted using streptavidin-conjugated IR 
dye to detect FN-biotin. Actin was used as the loading control for the (S) fraction. Right, 
quantitation showing fold difference between the amounts of FN-biotin in the DOC-fractionated 
(P) fraction in untreated and TGF-β1– or TGF-β2–treated cells. Data represent quantitation from 
two independent experiments. Error bars represent SEM. (F) Schematic of the recycling assay 
using Rh-FN upon incubation of cells with 20 µg/ml Rh-FN for 30 min at 37°C in the absence of 
TGF-β1 or TGF-β2. Cells are acid stripped to remove surface-bound Rh-FN (Internalized Rh-FN), 
followed by reincubation of cells in Rh-FN–free medium at 37°C for 1 h in the presence of 
TGF-β1 or TGF-β2. (G) Recycling assay as described in F; left, Rh-FN internalized by cells imaged 
after acid stripping using the Epi illumination and TIRF modes (90-nm penetration depth) as 
indicated to confirm removal of cell surface Rh-FN. Right, images taken under TIRF mode in 
either MCF10A or HFF cells, showing the 
reappearance of surface FN in cells untreated 
or treated with TGF-β1. Images are 
representative of at least three independent 
trials. Scale bar, 5 µm. Quantitation presented 
below was carried out using the 3D object 
counter on ImageJ as described in Materials 
and Methods after subtracting background 
from the cell-free regions. N = 10/condition. 
***p < 0.001.
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β1, and Rab11 colocalizes with active integ-
rin β1 and specifically regulates trafficking 
of the α5β1 heterodimer (Caswell et al., 
2007; Arjonen et al., 2012). To test whether 
FN colocalizes with Rab11 or Arf6 in re-
sponse to TGF-β, we determined the local-
ization of untreated and TGF-β–induced in-
ternalized FN pools with components of the 
major recycling pathways. We observed no 
significant colocalization between FN and 
Arf6 in TGF-β1– and TGF-β2–treated cells 
compared with untreated cells (Figure 5A). 
In contrast, both steady-state and TGF-β–
treated cells showed FN colocalization with 
Rab11 (Figure 5B). Moreover, TGF-β1 and 
TGF-β2 increased colocalization of FN with 
Rab11 by 1.7- and 1.4-fold, respectively 
(*p < 0.001; Figure 5B). Not all available FN 
was associated with Rab11. It is therefore 
possible that a fraction of internalized FN 
does not colocalize with Rab11 and may un-
dergo degradation (Sottile and Chandler, 
2005; Lobert et al., 2010) or recycle through 
alternate modes, including Rab4 (Roberts 
et al., 2001).
Owing to the observed colocalization of 
FN with Rab11 in response to TGF-β (Figure 
5B), we tested whether Rab11 was involved 
in FN recycling for fibrils. We carried out the 
recycling assay (as described in Figure 4F; 
Weigert and Donaldson, 2005) in cells trans-
fected with either GFP or Rab11-S25N, a 
dominant-negative Rab11 mutant that fails 
to recycle cargo proteins to the plasma 
membrane (Ren et al., 1998). Rh-FN was 
added to the cells for uptake, acid washed 
to remove surface bound Rh-FN, and al-
lowed to recover in medium containing ei-
ther serum or TGF-β as described in the 
schematic in Figure 4F, and the appearance 
of the fibrils was determined. In GFP-trans-
fected cells, we observed an increase in 
short Rh-FN fibrils in response to TGF-β 
(Figure 5C). However, in the Rab11-S25N 
transfectants, we observed no appearance 
of Rh-FN fibrils (Figure 5C), demonstrating 
that Rab11 function is required for TGF-β–
induced rapid FN fibrillogenesis. To confirm 
whether Rab11-S25N abolished cell surface 
fractions of FN fibrils as seen in Figure 5C, 
we used TIRF imaging. We consistently ob-
served significantly fewer cell surface fibrils 
in Rab11-S25N transfectants than in control 
cells (*p < 0.001; Figure 5, D and E). These 
data collectively demonstrate that FN uses 
the recycling protein Rab11 to return to the surface for enhanced 
fibrillogenesis.
DISCUSSION
In this study, we demonstrate a nontranscriptional mechanism by 
which TGF-β induces fibrillogenesis via enhanced FN trafficking. We 
find rapid fibrillogenesis in response to TGF-β1 and TGF-β2 in both 
Fibrillogenesis requires the recycling protein Rab11
Having observed FN recycling in response to TGF-β for fibrillogen-
esis (Figure 4), we next investigated the recycling pathways re-
quired for fibrillogenesis. Arf6 and Rab11 are two components of 
the major recycling pathways, with Rab11 playing roles in both 
TβRII and integrin recycling (Mitchell et al., 2004; Kobayashi and 
Fukuda, 2013). Specifically, Arf6 colocalizes with inactive integrin 
FIGURE 5: FN recycling and fibrillogenesis require the recycling protein Rab11. (A, B) MCF10A 
cells either untreated (serum alone) or treated with TGF-β1/TGF-β2 (10 ng/ml for 30 min) were 
coimmunostained using anti-FN and either (A) anti-Arf6 or (B) anti-Rab11 and imaged using 
confocal microscopy. Scale bar, 5 µm (main image), 1 µm (inset). Percentage colocalization from A 
and B was determined using the Coloc2 plug-in in ImageJ (Materials and Methods) from single 
z-plane between FN and either Arf6 or Rab11 in untreated compared with TGF-β1– or TGF-β2–
treated cells. Asterisk indicates significant differences in percentage colocalization (N > 15) 
between untreated compared with TGF-β1– or TGF-β2–treated cells (*p < 0.001, t test). Images 
are representative of at least three independent experiments. (C) Recycling assay as described in 
Figure 4F in the presence of Rh-FN in pEGFP and Rab11 (S25N)-GFP–transfected MCF10A cells. 
Cells either untreated (UN) or treated with 10 ng/ml TGF-β1 for 30 min were imaged. Only 
constructs expressing EGFP or Rab11(S25N)-GFP (as monitored by GFP expression) were imaged, 
and representative images are presented showing abrogated recycling of Rh-FN in Rab11 (S25N) 
transfectants. Arrowheads indicate fibrils. Scale bar, 2 µm. (D) MCF10A cells were transfected with 
pEGFP or Rab11 (S25N)-GFP as in C, immunostained using anti-FN after treatments with TGF-β1 
or TGF-β2 (10 ng/ml for 30 min), and imaged using TIRF microscopy (penetration depth, 110 nm). 
Scale bar, 5 µm. (E) Average fibril number/cell analyzed as described in Materials and Methods 
from TIRF images in GFP and Rab11 (S25N) mutants in untreated (UN) cells or cells treated with 
TGF-β1 or TGF-β2. Fibril lengths were tracked using the NeuronJ plug-in on ImageJ. Asterisk 
indicates significant differences (N = 10 [ANOVA]) in fibril number between untreated GFP 
transfectants for untreated (UN) cells and cells treated with TGF-β1 or TGF-β2 (*p < 0.001).
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nated/coupled to receptor trafficking. Integrins have, in turn, been 
shown to dictate ECM protein endocytosis and turnover (Panetti and 
McKeown-Longo, 1993; Shi and Sottile, 2008). However, evidence 
on the regulation of ECM traffic by growth factors and its effect on 
ECM remodeling is scarce. We find that FN is internalized and recy-
cled in the presence of TGF-β in a TβRII-dependent manner to be 
reused to form fibrils (Figure 4). Similarly, our patch/FRAP experi-
ments to measure interactions between the trafficking mutant TβRII 
S199 and integrin α5 demonstrate loss of the stable interaction be-
tween the two receptors (Figure 3) and less robust fibrils in the TβRII 
S199 transfectants (Figure 3). Thus fibrillogenesis requires the TβRII–
integrin α5β1 interaction. It is likely that the dominant-negative ef-
fects of TβRII S199 or TβRII ∆Cyto affect endogenous TβRII receptor 
and/or integrin trafficking and ultimately disrupt fibrillogenesis.
It was shown previously that fibronectin, along with integrin α5, 
internalizes and localizes to the lumen of multivesicular endosomes 
with EEA1, a prerequisite for integrin sorting and recycling (Lobert 
et al., 2010). Our data are the first demonstration of FN recycling af-
ter internalization (Figure 4). Whether TGF-β–induced FN trafficking 
and recycling occur concomitantly with active or inactive integrins, 
with or without TGF-β receptors, is the focus of our ongoing studies 
and will include analyzing the role of the catalytically active from of 
TβRII (TβRIIP525L; Carcamo et al., 1995), which is also signaling defi-
cient and has altered endocytosis and recycling in a cell type–depen-
dent manner (Anders et al., 1998; Dore et al., 1998, 2001). We antici-
pate that these future studies will provide insights into TGF-β 
receptor– integrin trafficking and their effect on matrix remodeling.
Our observations of FN localization with Rab11, which is in-
creased in the presence of TGF-β (Figure 5) and is required for fibril-
logenesis (Figure 5), suggest Rab11 as a recycling route for FN. 
However, we cannot completely rule out that a pool of FN may re-
cycle via Rab4, which has been shown to carry αvβ3 (Roberts et al., 
2001). Prior published routes on TβRII and integrin α5β1 trafficking 
showing that 1) TGF-β receptor internalized into early endosomes 
can recycle via Rab 11(Penheiter et al., 2002; Mitchell et al., 2004) 
and 2) integrin internalization via Rab5 endosomes can be recycled 
via Rab 11 (Pellinen and Ivaska, 2006; Arjonen et al., 2012), together 
with 3) our findings of FN recycling via Rab11 (Figure 5), indicate 
that a pool of FN recycles with integrin in a Rab11-dependent man-
ner, possibly along with TβRII. It is also likely that FN, integrin, and 
TβRII internalize into early endosomes concomitantly in response to 
TGF-β in either a clathrin/dynamin- or caveolin-dependent way. This 
is consistent with observations that endocytic trafficking via clathrin-
mediated endocytosis shifts the fate of TGF-β receptors from lyso-
somal degradation to prolonged signaling (Penheiter et al., 2002; 
Mitchell et al., 2004).
In conclusion, we provided new insights into growth factor–con-
trolled fibrillogenesis and showed, for the first time, that FN can be 
rapidly channeled into FN fibrils from available sources of FN within 
30 min. Whether this mechanism can complement transcriptionally 
induced FN function or exhibit distinct cellular functions remains to 
be examined. We anticipate that this nontranscriptional source of 
fibrillogenesis might play a significant role in rapid ECM remodeling 
and reinforcement of growth factor responses, particularly during 
events requiring precise spatial control of fibrillogenesis, with impli-
cations for cell migration, wound repair, and fibrosis.
MATERIALS AND METHODS
Cell line and culture conditions
Nontumorigenic MCF10A breast epithelial cells were obtained 
from the American Type Culture Collection and cultured in DMEM/
F12 (1:1) with 5% horse serum, epidermal growth factor (20 ng/ml), 
fibroblast and epithelial cells. We accomplished this by measuring 
incorporation of both exogenous and cell-produced FN into a 
DOC-insoluble matrix and visualizing at the cell surface using im-
munolabeling of FN and TIRF microscopy. Using the 49-mer FUD 
peptide to bind N-terminal sites on FN (Tomasini-Johansson et al., 
2006), we efficiently blocked incorporation of FN into the DOC-in-
soluble pool and fibril appearance induced by TGF-β (Figure 1), 
confirming the fibrillar nature of the rapid TGF-β response. TGF-β 
plays dominant roles in regulating cell motility and EMT (Wendt 
et al., 2012; Morrison et al., 2013), and we find fibrillogenesis in cells 
undergoing chemotactic migration (Figure 1J). TGF-β is also a ro-
bust inducer of cell motility and invasion in many cell types, includ-
ing epithelial cells that do not produce significant amounts of fibro-
nectin. However, TGF-β–induced cell migration is indeed repressed 
by the fibrillogenesis-blocking FUD peptide. Because our data sug-
gest that TGF-β–induced early fibrillogenesis uses recycled FN 
pools (Figures 4 and5) and does not require new protein synthesis 
(Figure 1D), we speculate that such rapid changes in the ECM that 
precede a transcriptional response are likely to be an important 
mechanism for triggering mechanical signals that can potentiate 
and sustain TGF-β responses.
We also discovered that TGF-β–induced fibrillogenesis requires 
the type II TGF-β receptor, using multiple cell models, including iso-
genic mink lung cells lacking the TβRII receptor (Laiho et al., 1990; 
Figure 2, B and C), and receptor silencing (Figure 2, D–G) in epithe-
lial cells. We also find that TβRII’s cytoplasmic domain is required to 
maintain steady-state levels of FN fibrils and is critical for TGF-β in-
duced fibrillogenesis (Figures 2 and 3). Such a requirement may 
stem from either the kinase activity of the receptor or loss of interac-
tions with the FN receptor integrin α5β1 mediated via TβRII’s cyto-
plasmic domain. Indeed, the interaction between integrin α5 and 
TβRII is reduced in the K277R mutant of TβRII (Figure 3). TGF-β can 
mediate both SMAD and non-SMAD responses, with TβRII phos-
phorylation by non–TGF-β receptor kinases such as Src being critical 
for bridging TGF-β and TβRII to non-SMAD mitogen-activated pro-
tein kinase activation (Feng and Derynck, 1996; Derynck and Zhang, 
2003; Galliher and Schiemann, 2007). Our data indicate that SMAD 
pathways are not involved in the rapid fibrillogenesis response due 
to the minor role of TβRI (Figures 2 and 3). These findings indicate 
that the initial fibrillogenesis response is a novel non-SMAD out-
come and could precede or be required for a longer-term SMAD 
response to maintain fibrillogenesis.
Our data from coimmunoprecipitation and PATCH/FRAP experi-
ments show stable cell surface interactions between TβRII and integ-
rins α5 and β1. Whether the activation state of the integrin α5β1 
heterodimer dictates the TβRII-integrin interaction remains to be 
determined. The interaction between TβRII and integrin α5 appears 
to be only marginally increased by FN (Figure 3), suggesting steady-
state complexes that are likely to result in constitutive trafficking of 
the bound ECM ligand. On the other hand, FN addition was able to 
immobilize a subpopulation of integrin β1 without cross-linking of 
TβRII. This may reflect fibronectin-mediated clustering of integrin β1 
that links it with the cytoskeleton and thus induces partial immobili-
zation (McKeown-Longo and Mosher, 1984; Bhatia et al., 1999). 
Whereas TGF-β receptor and integrin trafficking have been sepa-
rately examined previously (Yao et al., 2002; Caswell et al., 2009), 
there is limited knowledge on whether ECM components traffic 
along with the receptors. Both integrin α5β1 and TβRII undergo con-
stitutive endocytosis and recycling, with specific endocytosis and 
recycling routes influencing either receptor signaling or receptor 
turnover (Di Guglielmo et al., 2003; Lobert et al., 2010; Arjonen 
et al., 2012). Hence it is likely that ECM deposition may be coordi-
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was loaded alongside. This allows the internal comparison of FN 
ratios within the sample and between samples.
Transwell migration assay
Fifty thousand MCF10A cells in serum-free medium containing Rh-
FN were seeded in the upper chamber of a Transwell filter. The filter 
was coated on both sides with 10 µg/ml FN before the migration 
assay, and cells were allowed to migrate toward the lower chamber 
containing medium with 10% FBS (chemotactic gradient) for 6 h at 
37°C. Cells on the upper surface of the filter were removed, and 
only cells on the lower face of the filter were fixed in 4% paraformal-
dehyde and mounted using mount medium containing 4′6-diamid-
ino-2-phenylindole (DAPI).
Flow cytometry
Approximately 1 million cells were fixed in 70% ethanol and washed 
in ice-cold 1% bovine serum albumin (BSA) in PBS. The cell pellet 
was resuspended in 2 ml of ice-cold PBS and fixed in 5 ml of 100% 
ethanol added dropwise to keep the final ethanol concentration at 
70%. After fixing overnight at 20°C, the fixative was removed and 
the samples labeled with 10 µg/ml propidium iodide in 0.1% Triton 
X-100 with RNase and incubated for 20 min at room temperature. 
The samples were filtered and run on a BD LASRII Flow Cytometer.
Immunofluorescence and transfection
Cells were fixed in 4% paraformaldehyde, permeabilized in 0.3% 
Triton X-100, and blocked with 1% BSA in PBS. Primary antibody 
(1:200) incubation for 1 h was followed by 30 min of incubation 
with Dylight 800 conjugate (5151 Cell Signaling Technology). After 
washing, cells were stained with DAPI (Roche). Immunostaining of 
FN (1:100) to visualize fibrils was carried out by fixing in 4% para-
formaldehyde and permeabilized in 0.1% Triton X-100 for 1 min at 
4°C. Immunofluorescence imaging and z-stacking were performed 
using a Zeiss LSM700 confocal microscope. Transfection using Li-
pofectamine 2000 was carried out according to manufacturer’s 
instructions.
Microscopy
TIRF images were captured using a Leica AM inverted motorized 
microscope equipped with a Hamamatsu ImagEM back-thinned 
electron-multiplying cooled charge-coupled device camera. FN fi-
brils were imaged using the TIRF module at laser penetration depth 
of 110 or 90 nm as indicated (Leica HCX Plan Apo objective). Im-
munofluorescence imaging and z-stacking for colocalization analy-
ses were performed using a Zeiss LSM700 confocal microscope. 
Wide-field immunofluorescence images were imaged using the 
Olympus IX81 microscope connected to an Olympus 1XZ-UCB 
camera.
Statistical analyses and quantification
ImageJ was used to quantify pixel intensities of immunoblots. In 
Figure 4A, integrated pixel intensities were measured relative to 
surface area of the cells, and the data were acquired setting a con-
stant threshold of 43 for all the treatment conditions used. Be-
cause intensity values represented continuous data points, we 
used the nonparametric Mann-Whitney U test to calculate p value. 
Data are representative of multiple experiments. Colocalization 
analyses in Figure 5 were calculated from single z-planes from dif-
ferent regions of interest (ROIs) at a Coates significance of 1 and 
computed using the Coloc2 plug-in in ImageJ. Student’s t test was 
used to calculate p value. At least 50 different ROIs were included 
in a single analysis. Plots in Figures 1, 2, and 5 were constructed 
hydrocortisone (0.5 mg/ml), cholera toxin (100 ng/ml), and insulin 
(10 µg/ml). Human foreskin fibroblasts, COS7 cells, and mink lung 
epithelial cells MV1Lu, DR, and R1b were cultured in DMEM supple-
mented with 10% fetal bovine serum (FBS), and glutamine. Cell lines 
were maintained in 37°C humidified incubator buffered with 5% CO2.
Antibodies, reagents, and plasmids
Antibodies to FN (sc8422) and TβRII (sc220) were from Santa Cruz 
Biotechnology. Rabbit hemagglutinin (HA) tag (C29F4), integrin α5 
(4705S), and LAMP1 (D2D11) were from Cell Signaling Technology. 
The 9E10 mouse ascites against the myc tag (Evan et al., 1985) was 
from Covance Research Products (Denver, PA). Anti-myc IgG and 
monovalent Fab’ fragments were prepared from the 9E10 ascites 
as described (Henis et al., 1994). Alexa Fluor 488–goat anti-mouse 
IgG and Alexa Fluor 546–goat anti mouse F(ab′)2 were from Invitro-
gen-Molecular Probes (Eugene, OR); fluorescent F(ab′)2 was con-
verted to Fab’ as described (Gilboa et al., 1998). Rab11 (71-5300) 
was from Life Technologies, and Integrin α5 (P1D6) for immunopre-
cipitation was from the Developmental Studies Hybridoma Bank 
(University of Iowa, Iowa City, IA). Vinculin (CP74) was from Calbio-
chem, and β-actin (A2228) was from Sigma-Aldrich. Ligands TGF-β 
and FN were from R&D systems. Lipofectamine 2000 (11668019) 
was from Life Technologies. Nocodazole (358240100) was from 
Fisher, and CHX (94271-5G) was from Amresco. Rh-FN (FNR01 
and custom FNR04) and biotinylated FN (FNR03-A) were from 
Cytoskeleton. Propidium iodide (537059) was from Calbiochem. 
Plasmids expressing GFP-Rab11S25N (Choudhury et al., 2002; 
plasmid ID 12678), HA-tagged dynamin K44A (Song et al., 2004; 
plasmid ID 34683) and HA-tagged TβRII-∆Cyto (Siegel et al., 2003; 
plasmid ID 14051) were obtained from Addgene. The expression 
vectors encoding myc-tagged human TβRII, myc-TβRII S199, and 
myc-TβRI (in pcDNA3) were previously described (Ehrlich et al., 
2001; Yao et al., 2002). Integrin α5-RFP and integrin β1-GFP were 
constructed based on commercially obtained clones of the human 
receptors (OriGene); the coding regions were inserted N-terminally 
to monomeric RFP (Ehrlich et al., 2004) or enhanced GFP (EGFP) 
Clontech) by PCR.
TβRII knockdown
Two different Mission shRNA sequences from Sigma-Aldrich were 
used to knock down TβRII levels. shTβRII-1, 5′-CCGGATGGAAGA-
CTTTAAGGTATTTCTCGAGAAATACCTTAAAGTCTCCATTTT-
TTTG-3′; and shTβRII-2, 5′-CCGGCAATAACAAAGGCG CAAATAAC
TCGAGTTATTTGCGCCTTTGTTATTGTTTTTTG-3′.
Deoxycholate fractionation of FN
Deoxycholate fractionation of FN was carried out according to a 
previously published protocol (Sechler et al., 1996). Briefly, cells 
were washed in ice-cold phosphate-buffered saline (PBS), followed 
by lysate preparation in buffer containing 2% deoxycholate and 
0.02 M Tris-HCl, pH 8.8, supplemented with 2 mM phenyl-
methylsulfonyl fluoride, 2 mM EDTA, 2 mM iodoacetic acid, and 
2 mM N-ethylmalemide. Lysis was carried out by passing the lysate 
through a 23-gauge syringe needle several times, followed by incu-
bation on a rotor wheel for 30 min. The lysates were centrifuged at 
15,000 rpm for 30 min, and the supernatant was transferred to an-
other tube as the soluble fraction. The pellet/insoluble fraction was 
resuspended in SDS lysis buffer containing 1% SDS, 25 mM Tris-HCl, 
pH 8.0, and protease inhibitors. Lysates containing SDS were heated 
for 1 min at 95°C. In deoxycholate fractionation experiments, which 
involve the comparison of ratios between samples, the entire pellet 
fraction was loaded onto the gel, and 10% of the soluble fraction 
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2) Alexa Fluor 488 (or 546)–IgG goat anti-mouse (40 µg/ml). This 
protocol results in the myc-tagged receptors cross-linking and im-
mobilization by IgGs. In control experiments in which myc-TβRII or 
myc-TβRI was not cross-linked, the foregoing IgGs were replaced by 
equivalent monovalent Fab’ fragments. The integrin α5–RFP (or inte-
grin β1–GFP) in cells treated as described were subjected to FRAP 
and patch/FRAP studies as described earlier (Rechtman et al., 2009). 
The FRAP measurements were conducted at 15°C, replacing sam-
ples within 20 min to minimize internalization during the measure-
ment. An argon-ion laser beam (Innova 70C; Coherent, Santa Clara, 
CA) was focused through a fluorescence microscope (Axioimager.
D1; Carl Zeiss MicroImaging, Jena, Germany) to a Gaussian spot of 
0.77 ± 0.03 µm (Plan Apochromat 63×/1.4 numerical aperture oil-
immersion objective). After a brief measurement at monitoring inten-
sity (528.7 nm and 1 µW for RFP and 488 nm at similar conditions for 
GFP), a 5-mW pulse (20 ms) bleached 60–75% of the fluorescence in 
the illuminated region, and fluorescence recovery was followed by 
the monitoring beam. Values of D and Rf were extracted from the 
FRAP curves by nonlinear regression analysis, fitting to a lateral diffu-
sion process (Rechtman et al., 2009) Patch/FRAP studies were per-
formed similarly, except that IgG-mediated cross-linking/patching of 
a myc-tagged TGF-β receptor (described earlier) preceded the mea-
surement (Rechtman et al., 2009). This enables us to determine the 
effect of immobilizing one receptor type on the lateral diffusion of 
the coexpressed fluorescent protein, allowing identification of com-
plex formation between them and distinction between transient and 
stable interactions (Henis et al., 1990; Rechtman et al., 2009).
based on the observation that a fibril is considered a single track 
of at least 3 µm in length (Coussen et al., 2002; Lutz et al., 2011). 
A fibronectin trimer and a pentamer have been shown to form fi-
bril-like structures. The pentamer has a length of 90–100 nm 
(Coussen et al., 2002). Because the resolution of our microscope 
has a 200-nm limit, this made it unreliable to optically zoom into 
images to carry out quantification and analyses. A 3-µm cutoff was 
the smallest length that resembled a fibril, as opposed to an ag-
gregate of fibronectin as previously described (Lutz et al., 2011). 
Cells containing fibrils of such threshold lengths were counted as 
“with fibril” using the Neuron J plug-in on ImageJ and plotted. 
Analysis of variance (ANOVA) with Holm–Sidak test was used to 
calculate p values. Data are representative of multiple experi-
ments. Quantitation in Figure 4G was carried out using the three-
dimensional (3D) object counter on ImageJ. We set a grid on the 
TIRF images and introduced a size filter of >30 voxels. We picked 
the size cut-off based on background Rh signal noise, which was 
completely filtered out at >30 in cell free samples. We randomly 
analyzed 20 ROIs for 10 cells/condition.
Error bars in all experiments represent SEM.
Rhodamine FN–uptake experiments
This protocol is a modification to the published protocol (Weigert 
and Donaldson, 2005). Before measuring the uptake and recycling 
of Rh-FN, we serum starved cells for 6 h in medium containing 
20 µg/ml CHX. To measure uptake, the cells were incubated in 
20 µg/ml Rh-FN in serum-free medium for 30 min at 37°C to allow 
incorporation. To measure uptake, the coverslip was repeatedly 
washed in PBS, followed by two 30-s washes in acid stripping solu-
tion containing 0.5 M NaCl and 0.09 M acetic acid. The coverslips 
were rinsed again in ice-cold PBS and fixed for immunostaining. The 
efficiency of the acid stripping was determined using TIRF micros-
copy. To measure recycling, the acid-stripped coverslips were re-
turned to a 37°C incubator in medium containing serum and growth 
factors. After 1 h, the coverslips were repeatedly rinsed in PBS and 
fixed for immunostaining and visualization. Resurfacing of Rh-FN as 
measured by TIRF microscopy (penetration depth, 90 nm) was a 
measure of recycled FN, which was detectable only on the TIRF 
mode.
Biotinylation assay to measure recycled FN
Before biotinylation, cells were serum starved for 2 h and then incu-
bated with 20 µg/ml biotinylated FN (noncleavable) for 30 min at 
37°C in serum-free medium (steady state). The cells were repeatedly 
washed in PBS and allowed to recover in biotin-FN free medium for 
1 h at 37°C with or without 10 ng/ml TGF-β1 or TGF-β2. The lysates 
were DOC extracted into soluble (S) and insoluble (pellet [P]) frac-
tions and immunoblotted using streptavidin-conjugated IR Dye 
(926-32230; Li-Cor).
FRAP and patch/FRAP
FRAP and patch/FRAP were performed essentially as described pre-
viously (Henis et al., 1990; Rechtman et al., 2009). Briefly, at 48 h 
posttransfection, COS7 cells transfected with myc-TβRII, myc-TβRII 
S199, or myc-TβRI together with integrin α5-RFP or integrin β1-GFP 
were serum starved (30 min, 37°C), washed with cold Hanks’ balanced 
salt solution (HBSS) supplemented with 20 mM 4-(2-hydroxyethyl)-
1-piperazineethanesulfonic acid (HEPES; pH 7.2) and 2% BSA 
(Sigma-Aldrich), and blocked with normal goat γ-globulin (200 µg/ml, 
30 min, 4°C). They were then labeled successively at 4°C (to avoid 
internalization and enable exclusive cell surface labeling) in HBSS/
HEPES/BSA (45-min incubations) with 1) anti-myc IgG (40 µg/ml) and 
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